nach oben

Drugs & Aging

Erschienen in:

01.05.2005 | Leading Article

Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly

The Example of Licofelone

verfasst von: Arrigo F. G. Cicero, Giuseppe Derosa, Professor Antonio Gaddi

Erschienen in: Drugs & Aging | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

One of the categories of drugs most frequently used by the elderly, and probably the most commonly self-prescribed class of drug in this age group, is NSAIDs. However, NSAIDs are one of the primary causes of adverse drug reactions and are notorious for their gastric toxicity. They also inhibit renal function and reduce the efficacy of diuretics and ACE inhibitors, drugs that are commonly used by elderly patients.

Recent studies have shown that cyclo-oxygenase (COX)-2 is important in renal physiology. This means that selective COX-2 inhibitors, while undoubtedly safer than NSAIDs in terms of gastric toxicity, are not devoid of renal toxicity (in addition to their now clearly established adverse effects on coronary heart disease risk). Both the gastric and renal toxicities induced by traditional NSAIDs and selective COX-2 inhibitors seem to be related to inhibition of prostaglandin, but not leukotriene, synthesis. Maintaining the correct balance between prostaglandins and leukotrienes is essential for continuing good health, but both classes of mediators also play an important role in the pathogenesis of several diseases.

Recently, a new class of anti-inflammatory drugs, the lipoxygenase (LOX)/COX inhibitors, has been developed as a means of simultaneously inhibiting the synthesis of prostaglandins, thromboxanes and leukotrienes. Inhibition of leukotriene synthesis increases anti-inflammatory efficacy, particularly in rheumatic diseases, while reducing the risk of gastric damage. The LOX/COX inhibitor licofelone, which is currently in phase III trials, is the first of this new class and in the most advanced stage of development. Preliminary data with this drug seem promising, but further well designed clinical trials of this agent in the elderly will be necessary before a final evaluation is possible.

Patel P, Zed PJ. Drag-related visits to the emergency department: how big is the problem? Pharmacotherapy 2002; 22(7): 915–23PubMedCrossRef

Kaufman DW, Kelly JP, Rosenberg L, et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002; 287(3): 337–44PubMedCrossRef

Hochberg MC, Dougados M. Pharmacological therapy of osteoarthritis. Best Pract Res Clin Rheumatol 2001; 15(4): 583–93PubMedCrossRef

Jakobsson U, Hallberg IR. Pain and quality of life among older people with rheumatoid arthritis and/or osteoarthritis: a literature review. J Clin Nurs 2002; 11(4): 430–43PubMedCrossRef

Bertolini A, Ottani A, Sandrini M. Selective COX-2 inhibitors and dual acting anti-inflammatory drugs: critical remarks. Curr Med Chem 2002; 9: 1033–43PubMedCrossRef

Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29(3): 467–73PubMed

Martel-Pelletier J, Lajeunesse D, Reboul P, et al. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and nonselective non-steroidal anti-inflammatory drags. Ann Rheum Dis 2003; 62(5): 501–9PubMedCrossRef

Serhan CN. Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side. Arch Immunol Ther Exp 2001; 49(3): 177–88

Fiorucci S, Meli R, Bucci M, et al. Dual inhibitors of cyclooxygenase and 5-lipoxygenase: a new avenue in anti-inflammatory therapy? Biochem Pharmacol 2001; 62(11): 1433–8PubMedCrossRef

10.

Pope JE, Anderson JJ, Felson DT. A meta analysis of the effect of non-steroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153: 477–84PubMedCrossRef

11.

Johnson AG, Simons LA, Simons J, et al. Non-steroidal anti-inflammatory drags and hypertension in the elderly: a community based cross sectional study. Br J Clin Pharmacol 1993; 35: 455–9PubMedCrossRef

12.

Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease (Pt 2): short-term reductions in blood pressure — overview of randomised drug trials in their epidemiological context. Lancet 1990; 335(8693): 827–38PubMedCrossRef

13.

Clarke R, Shipley M, Lewington S, et al. Underestimation of risk associations due to regression dilution in long-term follow up of prospective studies. Am J Epidemiol 1999; 150(4): 341–53PubMedCrossRef

14.

Garcia Rodriguez LA, Varas C, Patrono C. Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drags in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000; 11(4): 382–7PubMedCrossRef

15.

Solomon DH, Schneeweiss S, Glynn RJ, et al. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 2004; 109: 2068–73PubMedCrossRef

16.

Konstam MA, Weir MR, Reicin A, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001; 104(19): 2280–8PubMedCrossRef

17.

Jüni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364: 2021–9PubMedCrossRef

18.

Okie S. Raising the safety bar: the FDA’s coxib meeting. N Engl J Med 2005; 352: 1283–5PubMedCrossRef

19.

Bykerk VP, Keystone EC. What are the goals and principles of management in the early treatment of rheumatoid arthritis? Best Pract Res Clin Rheumatol 2005; 19: 147–61PubMedCrossRef

20.

Andrieu S, Lebret M, Maclouf J, et al. Effects of antiaggregant and anti-inflammatory doses of aspirin on coronary hemodynamics and myocardial reactive hyperemia in conscious dogs. J Cardiovasc Pharmacol 1999; 33(2): 264–72PubMedCrossRef

21.

Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective — 1977. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol 1998; 51 Suppl.: 8–16

22.

Hohl CM, Dankoff J, Colacone A, et al. Polypharmacy, adverse drug-related events, and potential adverse drug interactions in elderly patients presenting to an emergency department. Ann Emerg Med 2001; 38(6): 666–71PubMedCrossRef

23.

Weaver AL. Rofecoxib: clinical pharmacology and clinical experience. Clin Ther 2001; 23(9): 1323–38PubMedCrossRef

24.

Watson DJ, Harper SE, Zhao PL, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 2000; 160(19): 2998–3003PubMedCrossRef

25.

Halter F, Tarnawski AS, Schmassmann A, et al. Cyclooxygenase 2: implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives. Gut 2001; 49(3): 443–53PubMedCrossRef

26.

Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000; 343: 1520–8PubMedCrossRef

27.

Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55PubMedCrossRef

28.

Boers M. NSAIDs and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection. Lancet 2001; 357: 1222–4PubMedCrossRef

29.

DeMaria AN. NSAIDs, COXIBs and cardio-renal physiology. In: Health Science Center for Continuing Medical Education, editor. San Diego (CA), 2000: Health Science Center for Continuing Medical Education, 1–37

30.

Welthon A. Renal and related cardiovascular effects of conventional and COX-2 specific NSAIDs and non-NSAID analgesics. Am J Ther 2000; 7: 63–74CrossRef

31.

Harris CJ, Brater DC. Renal effects of cyclooxygenase-2 selective inhibitors. Curr Opin Nephrol Hypertens 2001; 10(5): 603–10PubMedCrossRef

32.

Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet: a randomized, controlled trial. Ann Intern Med 2000; 133(1): 1–9PubMed

33.

Appel GB. COX-2 inhibitors and the kidney. Clin Exp Rheumatol 2001; 19(S): 37–40

34.

Ailabouni W, Eknoyan G. Nonsteroidal anti-inflammatory drugs and acute renal failure in the elderly: a risk-benefit assessment. Drugs Aging 1996; 9(5): 341–51PubMedCrossRef

35.

Clarkson MR, McGinthy A, Godson C, et al. Leucotryenes and lipoxins: lipooxygenase-derived modulators of leukocyte recruitment and vascular tone in glomeruloneprhitis. Nephrol Dial Transplant 1998; 13: 3043–51PubMedCrossRef

36.

Deray G. Renal tolerance to selective inhibitors of cyclooxygenase type 2. Presse Med 2001; 30: 1507–12PubMed

37.

Whelton A, Braler DC, Sica DA. Effects of cycloxygenase-2 inhibition on renal function in the elderly [abstract]. J Am Soc Nephr 1999; 10: 92A

38.

Hanlon JT, Schmader KE, Koronoswki MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997; 45: 945–8PubMed

39.

Parente L. Pros and cons of selective inhibition of cyclooxygenase-2 versus dual lipoxygenase/cyclooxygenase inhibition: is two better than one? J Rheumatol 2001; 28(11): 2375–82PubMed

40.

Dahlén S-E. 5-Lipoxygenase inhibitors. In: Hansel TT, Barnes PJ, editors. New drugs for asthma, allergy and COPD. Progress in Respiratory Research. Vol. 31. Basel: Karger, 2001: 115–20CrossRef

41.

Petty TL. COPD in perspective. Chest 2002; 121 (5 Suppl.): 116S–20SPubMedCrossRef

42.

Gaddi A, Cicero AFG, Pedro E. Clinical perspectives of anti-inflammatory therapy in the elderly: the lypoxigenase (LOX)/cycloxigenase (COX) inhibition concept. Arch Gerontol Geriatr 2004; 38(3): 201–12PubMedCrossRef

43.

Lajeunesse D, Paredes Y, Massicotte F, et al. Role of leukotriene B4 in the abnormal function of human subcondral osteoarthritic osteoblasts: effect of the combined inhibition of cyclooxygenase and 5-lipoxygenase (5-LOX) by licofelone (ML3000). In: EULAR 2002, Annual European Congress of Rheumatology; 2002 June 12–15; Stockholm, Sweden. Ann Rheum Dis 2002; 61(S1): 175

44.

Leval X, Julemont F, Delarge J, et al. New trends in dual 5-LOX/COX inhibition. Curr Med Chem 2002; 9(9): 941–62PubMedCrossRef

45.

Celotti F, Laufer S. Anti-inflammatory drugs: new multitarget compounds to face an old problem: the dual inhibition concept. Pharmacol Res 2001; 43(5): 429–36PubMedCrossRef

46.

Rabasseda X, Mealy N, Castaner J. ML-3000. Drugs Future 1995; 20: 1007–9

47.

Laufer S, Tries S, Augustin J, et al. Pharmacological profile of a new pyrrolizine derivative inhibiting the enzymes cyclooxygenase and 5-lipoxygenase. Arzneimittelforschung 1994; 44: 629–36PubMed

48.

Abraham WM, Laufer S, Tries S. The effects of ML 3000 on antigen-induced responses in sheep. Pulm Pharmacol Ther 1997; 10: 167–73PubMedCrossRef

49.

Laufer S, Tries S, Augustin J, et al. Acute and chronic anti-inflammatory properties of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. Arzneimittelforschung 1995; 45: 27–32PubMed

50.

Rotondo S, Krauze Brzosko K, et al. Licofelone, an inhibitor of cyclooxygenase and 5-lipoxygenase, specifically inhibits cyclooxygenase-1-dependent platelet activation. Eur J Pharmacol 2004; 488(1–3): 79–83PubMedCrossRef

51.

Rotondo S, Dell’Elba G, Krauze Brzosko K, et al. Licofelone, a dual lipoxygenase-cyclooxygenase inhibitor, downregulates polymorphonuclear leukocyte and platelet. Eur J Pharmacol 2002; 453(1): 131–9PubMedCrossRef

52.

Algate DR, Augustin J, Atterson PR, et al. General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals. Arzneimittelforschung 1995; 45: 159–16PubMed

53.

Heidemann A, Tries S, Laufer S, et al. Studies on the in vitro and in vivo genotoxicity of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid. Arzneimittel Forschung 1995; 45: 486–90PubMed

54.

Wallace JL, Carter L, McKnight W, et al. ML 3000 reduces gastric prostaglandin synthesis without causing mucosal injury. Eur J Pharmacol 1994; 271: 525–31PubMedCrossRef

55.

Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002; 51(3): 135–43PubMedCrossRef

56.

Fiorucci S, Distrutti E, De Lim OM, et al. Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003; 17(9): 1171–3PubMed

57.

Buchner A, Bias P, Lammerich A. Twice the therapeutic dose of licofelone — an inhibitor of COX-1, COX-2 and 5-LOX — results in a significantly lower gastrointestinal ulcer incidence than naproxen in osteoarthritis patients, when administered with or without concomitant low-dose aspirin [abstract]. Ann Rheum Dis 2003; 62Suppl. 1: 261

58.

Gay RE, Neidhart M, Pataky F, et al. Dual inhibition of 5-lipoxygenase and cyclooxygenase 1 and 2 by ML3000 reduces joint destruction in adjuvant arthritis. J Rheumatol 2001; 28: 2060–5PubMed

59.

Jovanovic DV, Fernandes JC, Martel-Pelletier J, et al. In vivo dual inhibition of cyclooxygenase and lipoxygenase by ML-3000 reduces the progression of experimental osteoarthritis. Arthritis Rheum 2001; 44: 2320–30PubMedCrossRef

60.

Pelletier J-P, Di Battista JA, Raynoud JP, et al. The in vivo effects of intraarticular corticosteroid injections on cartilage lesions, stromelysin, interleukin-1 and oncogene protein synthesis in experimental osteoarthritis. Lab Invest 1995; 72: 578–86PubMed

61.

Sipe JD, Bartle LM, Loose LD. Modification of proinflammatory cytokine production by the antirheumatic agents tenidap and naproxen: a possible correlate with clinical acute phase response. J Immunol 1992; 148: 480–4PubMed

62.

Pelletier J-P, Lajennesse D, Jovanovic DV, et al. Carprofen simultaneously reduces progression of morphological changes in cartilage and subchondral bone in experimental dog osteoarthritis. J Rheumatol 2000; 27: 2893–902PubMed

63.

Pelletier J-P, Martel-Pelletier J. In vivo protective effects of prophylactic treatment with tiaprofenic acid or intraarticular corticosteroids on osteoarthritic lesions in the experimental dog model. J Rheumatol Suppl 1991; 27: 127–30PubMed

64.

Palmoski MJ, Brandt KD. In vivo effect of aspirin on canine osteoarthritic cartilage. Arthritis Rheum 1983; 26: 994–1001PubMedCrossRef

65.

Paredes Y, Massicotte F, Pelletier J-P, et al. Study of the role of leukotriene B4 in abnormal function of human subchondral osteoarthritis osteoblasts: effects of cyclooxygenase and/or 5-lipoxygenase inhibition. Arthritis Rheum 2002; 46(7): 1804–12PubMedCrossRef

66.

Rainsford KD, Ying C, Smith F. Effects of 5-lipoxygenase inhibitors on interleukin production by human synovial tissues in organ culture; comparison with interleukin-1-synthesis inhibitors. J Pharm Pharmacol 1996; 48: 46–52PubMedCrossRef

67.

Bias P, Buchner A, Klesser B, et al. The gastrointestinal tolerability of the LOX/COX inhibitor, licofelone, is similar to placebo and superior to naproxen therapy in healthy volunteers: results from a randomized, controlled trial. Am J Gastroenterol 2004; 99(4): 611–8PubMedCrossRef

68.

Reginster JY, Bias P, Buchner A. First clinical results of licofelone (ML3000), an inhibitor of COX-1, COX-2 and 5-LOX, for the treatment of osteoarthtritis. Ann Rheum Dis 2002; 61 (1 Suppl.): 116

69.

Bias P, Buchner A, Lammerich A. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, has an excellent tolerability profile when given in single doses of up to 16-fold the therapeutic dose [abstract]. Ann Rheum Dis 2003; 62Suppl. 1: 479

70.

Blanco FJ, Buchner A, Bias P, et al. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as naproxen and shows improved safety during 12 months of treatment in patients with osteoarthritis of the knee [abstract]. Ann Rheum Dis 2003; 62Suppl. 1: 261

71.

Pavelka K, Bias P, Buchner A, et al. Licofelone, an inhibitor of COX-1, COX-2 and 5-LOX, is as effective as celecoxib and shows improved tolerability during 12 weeks of treatment in patients with osteoarthritis of the knee [abstract]. Ann Rheum Dis 2003; 62Suppl. 1: 261

Titel: Combined Lipoxygenase/Cyclo-oxygenase Inhibition in the Elderly
The Example of Licofelone
verfasst von: Arrigo F. G. Cicero
Giuseppe Derosa
Professor Antonio Gaddi
Publikationsdatum: 01.05.2005
Verlag: Springer International Publishing
Erschienen in: Drugs & Aging / Ausgabe 5/2005
Print ISSN: 1170-229X
Elektronische ISSN: 1179-1969
DOI: https://doi.org/10.2165/00002512-200522050-00004

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2005

Predicting and Preventing Adverse Drug Reactions in the Very Old

The Impact of Age on Rejection in Kidney Transplantation

Dextropropoxyphene

Switching of Prescription Drugs to Over-the-Counter Status

Improving Elder Care by Integrating Geriatric Expertise into Medicare